Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 10/20 | 0.46 |
| ▸ | RAB9A | P51151 | 10/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MDH1 | P40925 | 1/20 | 0.43 |
| ▸ | MDH2 | P40926 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560515 | 1.00 | GAA (0.49) | GAANPSR1MEN1KMT2ANPC1 | |
| SCHEMBL13883482 | 1.00 | GAA (0.49) | GAANPSR1MEN1KMT2ANPC1 | |
| SCHEMBL17560611 | 0.87 | HTR1D (0.45) | GAANPSR1MEN1KMT2ATSHR | |
| SCHEMBL17560614 | 0.87 | HTR1D (0.45) | GAANPSR1MEN1KMT2ATSHR | |
| SCHEMBL13883857 | 0.87 | HTR1D (0.45) | GAANPSR1MEN1KMT2ATSHR | |
| SCHEMBL28713631 | 0.84 | WNT3A (0.43) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL29544744 | 0.84 | WNT3A (0.43) | MEN1KMT2ASMN1; SMN2TSHRMAPT | |
| SCHEMBL993933 | 0.83 | GAA (0.64) | GAANPSR1MEN1KMT2ANPC1 | |
| SCHEMBL10092627 | 0.82 | CYP17A1 (0.48) | NAMPTSMN1; SMN2 | |
| SCHEMBL14155353 | 0.82 | CYP17A1 (0.48) | NAMPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-08-24 | — | — | US | disclosed |
| WO-2016034642-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240544-A1 | ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | TP53, KRAS, AQP1 | GAA 2238/4885NPSR1 3877/4885MEN1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.